Croda partners with Amino to enhance global access to high-purity amino acids, boosting biopharma manufacturing efficiency and supporting next-generation biologic therapies.
Croda International Plc, widely recognised for applying smart science to create advanced ingredients and technologies that enhance everyday life, has announced a new strategic supply partnership with Amino GmbH. Amino is a well-established producer of pharmaceutical-grade amino acids, and this collaboration is designed to significantly strengthen the global supply and availability of ultra-high-purity amino acids used in pharmaceutical formulations and modern biomanufacturing.
Amino acids serve as the essential building blocks of proteins, which are fundamental components of nearly all biological structures and functions, including cellular architecture, enzymatic activity, and the formation of various therapeutic molecules. In the pharmaceutical sector, amino acids play a dual role: they are used as excipients to help stabilise and formulate advanced biologic therapies, and they act as critical raw materials in the production of biologics such as monoclonal antibodies. As demand for biologic drugs continues to rise, ensuring consistent access to high-purity amino acids has become increasingly important for manufacturers aiming to scale production efficiently and meet stringent regulatory expectations.
Commenting on the collaboration, Thomas Riermeier, President of Life Sciences at Croda, highlighted the value this partnership will bring to the rapidly advancing biopharmaceutical ecosystem. He noted that combining Croda’s scientific knowledge and global commercial presence with Amino’s specialised production capabilities will empower biopharma developers to streamline their manufacturing processes. This, in turn, supports the creation of transformative therapies that have the potential to redefine patient outcomes.
The alliance is also aligned with Croda’s broader strategy to expand its support for customers operating in the fast-developing biopharmaceutical landscape. According to Katie Dec, Global Business Director for Croda Pharma Insights, Amino’s strong industry reputation and technical depth make them an ideal collaborator. She emphasised that the partnership will help accelerate access to dependable, high-quality materials essential for bringing the next generation of biological treatments to market. Dec also revealed that Croda will introduce a new BioXPro™ range—featuring high-purity histidine and arginine amino acids—starting in January. These new products will offer the high levels of purity, consistency, and reproducibility that customers increasingly prioritise.
For Amino GmbH, the partnership represents both a major achievement and a catalyst for future growth in the biopharmaceutical sector. Lutz Thomas, Managing Director at Amino, stated that Croda’s extensive market reach, combined with Amino’s precision manufacturing expertise, creates a partnership uniquely positioned to meet evolving customer requirements with accuracy and reliability.
This collaboration further strengthens Croda’s commitment to delivering the highest-purity inputs for pharmaceutical formulation and bioprocessing. It also builds upon the company’s recent innovations, including the release of Virodex™, a solution designed for viral inactivation and cell lysis, and Super Refined™ Poloxamer 188, used to protect cells from shear stress in culture media. Through continued investment in partnerships and technologies, Croda aims to equip the global biopharma industry with the trusted materials needed to accelerate therapeutic innovation.
